DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

7.29 0.05 (0.69%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MACK $7.29 0.69%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $7.28
Previous Close $7.24
Daily Range $6.97 - $7.30
52-Week Range $2.05 - $8.25
Market Cap $762.4M
P/E Ratio -6.30
Dividend (Yield) $0.00 (0.0%)
Volume 1,696,460
Average Daily Volume 1,406,203
Current FY EPS -$0.96

Sector

Healthcare

Industry

Drugs

Merrimack Pharmaceuticals, Inc. (MACK) Description

Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases with an initial focus on cancer. Website: http://www.merrimackpharma.com/

News & Commentary Rss Feed

Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today

The stock market finally headed lower after a long run of winning sessions, but these stocks still held up well. Find out why.

After Hours Most Active for Sep 15, 2014 : QQQ, VMW, BAC, MACK, OXY, YOKU, SIRI, AA, CAT, MSFT, CSC

After Hours Most Active for Sep 15, 2014 : QQQ, VMW, BAC, MACK, OXY, YOKU, SIRI, AA, CAT, MSFT, CSCO, ERIC

5 Stocks Under $10 Soaring Higher

Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Ta

Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape

Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the

Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape

3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus

Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tap

Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape

Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2014 Results - Earnings Call Transcript

Update: Merrimack Earnings - Looming Concerns Still Remain

Is Now The Time To Buy Merrimack Pharmaceuticals?

Insiders Buy the Holdings of XBI ETF

See More MACK News...